1
|
Duan X, Bai W, Hu J, Wu J, Tan H, Wang F, Lang X, Wang B, Hu J. Inhibitory effect of flavonoids on multidrug and toxin extrusion protein 1 function: Implications for food/herb-drug interaction and drug-induced kidney injury. J Appl Toxicol 2024; 44:1388-1402. [PMID: 38760888 DOI: 10.1002/jat.4628] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2024] [Revised: 04/29/2024] [Accepted: 04/30/2024] [Indexed: 05/20/2024]
Abstract
Multidrug and toxin extrusion protein 1 (MATE1), an efflux transporter mainly expressed in renal proximal tubules, mediates the renal secretion of organic cationic drugs. The inhibition of MATE1 will impair the excretion of drugs into the tubular lumen, leading to the accumulation of nephrotoxic drugs in the kidney and consequently potentiating nephrotoxicity. Screening and identifying potent MATE1 inhibitors can predict or minimize the risk of drug-induced kidney injury. Flavonoids, a group of polyphenols commonly found in foodstuffs and herbal products, have been reported to cause transporter-mediated food/herb-drug interactions. Our objective was to investigate the inhibitory effects of flavonoids on MATE1 in vitro and in vivo and to assess the effects of flavonoids on cisplatin-induced kidney injury. Thirteen flavonoids exhibited significant transport activity inhibition (>50%) on MATE1 in MATE1-MDCK cells. Among them, the six strongest flavonoid inhibitors, including irisflorentin, silymarin, isosilybin, sinensetin, tangeretin, and nobiletin, markedly increased cisplatin cytotoxicity in these cells. In cisplatin-induced in vivo renal injury models, irisflorentin, isosilybin, and sinensetin also increased serum creatinine and blood urea nitrogen levels to different degrees, especially irisflorentin, which exhibited the most potent nephrotoxicity with cisplatin. The pharmacophore model indicated that the hydrogen bond acceptors at the 3, 5, and 7 positions may play a critical role in the inhibitory effect of flavonoids on MATE1. Our findings provide helpful information for predicting the potential risks of flavonoid-containing food/herb-drug interactions and avoiding the exacerbation of drug-induced kidney injury via MATE1 mediation.
Collapse
Affiliation(s)
- Xiaoyan Duan
- State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing Key Laboratory of Non-Clinical Drug Metabolism and PK/PD study, Beijing Key Laboratory of Active Substances Discovery and Drug Ability Evaluation, Department of Drug Metabolism, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
| | - Wanting Bai
- State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing Key Laboratory of Non-Clinical Drug Metabolism and PK/PD study, Beijing Key Laboratory of Active Substances Discovery and Drug Ability Evaluation, Department of Drug Metabolism, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
| | - Jiahuan Hu
- State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing Key Laboratory of Non-Clinical Drug Metabolism and PK/PD study, Beijing Key Laboratory of Active Substances Discovery and Drug Ability Evaluation, Department of Drug Metabolism, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
| | - Jinjin Wu
- State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing Key Laboratory of Non-Clinical Drug Metabolism and PK/PD study, Beijing Key Laboratory of Active Substances Discovery and Drug Ability Evaluation, Department of Drug Metabolism, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
| | - Huixin Tan
- State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing Key Laboratory of Non-Clinical Drug Metabolism and PK/PD study, Beijing Key Laboratory of Active Substances Discovery and Drug Ability Evaluation, Department of Drug Metabolism, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
| | - Fenghe Wang
- State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing Key Laboratory of Non-Clinical Drug Metabolism and PK/PD study, Beijing Key Laboratory of Active Substances Discovery and Drug Ability Evaluation, Department of Drug Metabolism, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
| | - Xuli Lang
- State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing Key Laboratory of Non-Clinical Drug Metabolism and PK/PD study, Beijing Key Laboratory of Active Substances Discovery and Drug Ability Evaluation, Department of Drug Metabolism, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
| | - Baolian Wang
- State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing Key Laboratory of Non-Clinical Drug Metabolism and PK/PD study, Beijing Key Laboratory of Active Substances Discovery and Drug Ability Evaluation, Department of Drug Metabolism, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
| | - Jinping Hu
- State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing Key Laboratory of Non-Clinical Drug Metabolism and PK/PD study, Beijing Key Laboratory of Active Substances Discovery and Drug Ability Evaluation, Department of Drug Metabolism, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
| |
Collapse
|
2
|
Sulaimani N, Houghton MJ, Bonham MP, Williamson G. Effects of (Poly)phenols on Circadian Clock Gene-Mediated Metabolic Homeostasis in Cultured Mammalian Cells: A Scoping Review. Adv Nutr 2024; 15:100232. [PMID: 38648895 PMCID: PMC11107464 DOI: 10.1016/j.advnut.2024.100232] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2023] [Revised: 04/02/2024] [Accepted: 04/16/2024] [Indexed: 04/25/2024] Open
Abstract
Circadian clocks regulate metabolic homeostasis. Disruption to our circadian clocks, by lifestyle behaviors such as timing of eating and sleeping, has been linked to increased rates of metabolic disorders. There is now considerable evidence that selected dietary (poly)phenols, including flavonoids, phenolic acids and tannins, may modulate metabolic and circadian processes. This review evaluates the effects of (poly)phenols on circadian clock genes and linked metabolic homeostasis in vitro, and potential mechanisms of action, by critically evaluating the literature on mammalian cells. A systematic search was conducted to ensure full coverage of the literature and identified 43 relevant studies addressing the effects of (poly)phenols on cellular circadian processes. Nobiletin and tangeretin, found in citrus, (-)-epigallocatechin-3-gallate from green tea, urolithin A, a gut microbial metabolite from ellagitannins in fruit, curcumin, bavachalcone, cinnamic acid, and resveratrol at low micromolar concentrations all affect circadian molecular processes in multiple types of synchronized cells. Nobiletin emerges as a putative retinoic acid-related orphan receptor (RORα/γ) agonist, leading to induction of the circadian regulator brain and muscle ARNT-like 1 (BMAL1), and increased period circadian regulator 2 (PER2) amplitude and period. These effects are clear despite substantial variations in the protocols employed, and this review suggests a methodological framework to help future study design in this emerging area of research.
Collapse
Affiliation(s)
- Noha Sulaimani
- Department of Nutrition, Dietetics and Food, Monash University, Notting Hill, Australia; Victorian Heart Institute, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Australia; Department of Food and Nutrition, King Abdulaziz University, Jeddah, Saudi Arabia
| | - Michael J Houghton
- Department of Nutrition, Dietetics and Food, Monash University, Notting Hill, Australia; Victorian Heart Institute, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Australia
| | - Maxine P Bonham
- Department of Nutrition, Dietetics and Food, Monash University, Notting Hill, Australia
| | - Gary Williamson
- Department of Nutrition, Dietetics and Food, Monash University, Notting Hill, Australia; Victorian Heart Institute, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Australia.
| |
Collapse
|
3
|
Ito H, Negoro H, Kono J, Hayata N, Miura T, Manabe Y, Miyazaki Y, Mishina M, Woo JT, Sakane N, Okuno H. Effectiveness and Safety of a Mixture of Nobiletin and Tangeretin in Nocturia Patients: A Randomized, Placebo-Controlled, Double-Blind, Crossover Study. J Clin Med 2023; 12:2757. [PMID: 37109094 PMCID: PMC10143228 DOI: 10.3390/jcm12082757] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2023] [Revised: 03/29/2023] [Accepted: 04/03/2023] [Indexed: 04/29/2023] Open
Abstract
Nobiletin and tangeretin (NoT) are flavonoids derived from the peel of Citrus depressa, and they have been found to modulate circadian rhythms. Because nocturia can be considered a circadian rhythm disorder, we investigated the efficacy of NoT for treating nocturia. A randomized, placebo-controlled, double-blind, crossover study was conducted. The trial was registered with the Japan Registry of Clinical Trials (jRCTs051180071). Nocturia patients aged ≥50 years who presented nocturia more than 2 times on a frequency-volume chart were recruited. Participants received NoT or a placebo (50 mg once daily for 6 weeks), followed by a washout period of ≥2 weeks. The placebo and NoT conditions were then switched. Changes in nocturnal bladder capacity (NBC) were the primary endpoint, and changes in nighttime frequency and nocturnal polyuria index (NPi) were secondary endpoints. Forty patients (13 women) with an average age of 73.5 years were recruited for the study. Thirty-six completed the study, while four withdrew. No adverse events directly related to NoT were observed. NoT had little effect on NBC compared with the placebo. In contrast, NoT significantly changed nighttime frequency by -0.5 voids compared with the placebo (p = 0.040). The change in NPi from baseline to the end of NoT was significant (-2.8%, p = 0.048). In conclusion, NoT showed little change in NBC but resulted in decreased nighttime frequency with a tendency toward reduced NPi.
Collapse
Affiliation(s)
- Haruki Ito
- Department of Urology, National Hospital Organization, Kyoto Medical Center, Kyoto 612-8555, Japan
| | - Hiromitsu Negoro
- Department of Urology, Institute of Medicine, University of Tsukuba, Tsukuba 305-8575, Japan
| | - Jin Kono
- Department of Urology, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan
| | - Naoki Hayata
- Department of Urology, National Hospital Organization, Kyoto Medical Center, Kyoto 612-8555, Japan
| | - Takayoshi Miura
- Department of Urology, National Hospital Organization, Kyoto Medical Center, Kyoto 612-8555, Japan
| | - Yumi Manabe
- Department of Urology, National Hospital Organization, Kyoto Medical Center, Kyoto 612-8555, Japan
| | - Yu Miyazaki
- Department of Urology, National Hospital Organization, Kyoto Medical Center, Kyoto 612-8555, Japan
| | - Mutsuki Mishina
- Department of Urology, National Hospital Organization, Kyoto Medical Center, Kyoto 612-8555, Japan
| | - Je Tae Woo
- Department of Biological Chemistry, College of Bioscience and Biotechnology, Chubu University, Kasugai 487-8501, Japan
| | - Naoki Sakane
- Division of Preventive Medicine, Clinical Research Institute, National Hospital Organization, Kyoto Medical Center, Kyoto 612-8555, Japan
| | - Hiroshi Okuno
- Department of Urology, National Hospital Organization, Kyoto Medical Center, Kyoto 612-8555, Japan
| |
Collapse
|
4
|
Kong J, Wang C, Duan X, Shi H, Xue C, Wei Z, Huang Q, Zhang T, Wang Y. Dietary Antarctic Krill Oil Enhances the Oral Bioavailability of Nobiletin but Has No Ideal Synergistic Effect on Improving Memory and Cognition Ability in Aβ
1–42
Induced Rats. EUR J LIPID SCI TECH 2022. [DOI: 10.1002/ejlt.202200049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Jing‐Ya Kong
- College of Food Science and Engineering Ocean University of China Qingdao 266003 China
| | - Cheng‐Cheng Wang
- College of Food Science and Engineering Ocean University of China Qingdao 266003 China
| | - Xue‐Feng Duan
- College of Food Science and Engineering Ocean University of China Qingdao 266003 China
| | - Hao‐Hao Shi
- College of Food Science and Engineering Ocean University of China Qingdao 266003 China
| | - Chang‐Hu Xue
- College of Food Science and Engineering Ocean University of China Qingdao 266003 China
- Laboratory for Marine Drugs and Bioproducts Pilot National Laboratory for Marine Science and Technology (Qingdao) Qingdao Shandong Province 266237 P. R. China
| | - Zi‐Hao Wei
- College of Food Science and Engineering Ocean University of China Qingdao 266003 China
| | - Qing‐Rong Huang
- Department of Food Science, School of Environmental and Biological Sciences, Rutgers The State University of New Jersey New Brunswick NJ 08901 USA
| | - Tian‐Tian Zhang
- College of Food Science and Engineering Ocean University of China Qingdao 266003 China
| | - Yu‐Ming Wang
- College of Food Science and Engineering Ocean University of China Qingdao 266003 China
- Laboratory for Marine Drugs and Bioproducts Pilot National Laboratory for Marine Science and Technology (Qingdao) Qingdao Shandong Province 266237 P. R. China
| |
Collapse
|
5
|
Zhang J, Fan M, Yu X, Zhang B. The pharmacokinetic study on the interaction between nobiletin and anemarsaponin BII in vivo and in vitro. PHARMACEUTICAL BIOLOGY 2021; 59:1528-1532. [PMID: 34726569 PMCID: PMC8567955 DOI: 10.1080/13880209.2021.1990355] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 06/17/2021] [Revised: 08/22/2021] [Accepted: 09/26/2021] [Indexed: 06/13/2023]
Abstract
CONTEXT The interaction between nobiletin and anemarsaponin BII could affect the pharmacological activity of these two drugs during their combination. OBJECTIVE The co-administration of nobiletin and anemarsaponin BII was investigated to explore the interaction and the potential mechanism. MATERIALS AND METHODS Male Sprague-Dawley rats were only orally administrated with 50 mg/kg nobiletin as the control and another six rats were pre-treated with 100 mg/kg anemarsaponin BII for 7 d followed by the administration of nobiletin. The transport and metabolic stability of nobiletin were evaluated in vitro, and the effect of anemarsaponin BII on the activity of CYP3A4 was also assessed to explore the potential mechanism underlying the interaction. RESULTS The increasing Cmax (2309.67 ± 68.06 μg/L vs. 1767.67 ± 68.86 μg/L), AUC (28.84 ± 1.34 mg/L × h vs. 19.57 ± 2.76 mg/L × h), prolonged t1/2 (9.80 ± 2.33 h vs. 6.24 ± 1.53 h), and decreased clearance rate (1.46 ± 0.26 vs. 2.42 ± 0.40) of nobilein was observed in rats. Anemarsaponin BII significantly enhanced the metabolic stability of nobiletin in rat liver microsomes (half-life increased from 31.56 min to 39.44 min) and suppressed the transport of nobiletin in Caco-2 cells (efflux rate decreased from 1.57 ± 0.04 to 1.30 ± 0.03). The inhibitory effect of anemarsaponin BII on CYP3A4 was also found with an IC50 value of 10.23 μM. DISCUSSION AND CONCLUSIONS The interaction between anemarsaponin BII and nobiletin was induced by the inhibition of CYP3A4, which should draw special attention in their clinical co-administration.
Collapse
Affiliation(s)
- Jie Zhang
- Department of Medicinal Medicine, The Second Hospital of Shandong University, Jinan, Shandong, China
| | - Meiling Fan
- Department of Medicine, Qingdao Municipal Hospital (East Campus), Qingdao, Shandong, China
| | - Xia Yu
- Department of Anesthesia and Perioperative Medicine, Dongying Hospital of Traditional Chinese Medicine, Dongying, Shandong, China
| | - Bin Zhang
- Department of Medicinal Medicine, The Second Hospital of Shandong University, Jinan, Shandong, China
| |
Collapse
|
6
|
Miao H, Wu XQ, Wang YN, Chen DQ, Chen L, Vaziri ND, Zhuang S, Guo Y, Su W, Ma SX, Zhang HQ, Shang YQ, Yu XY, Zhao YL, Mao JR, Gao M, Zhang JH, Zhao J, Zhang Y, Zhang L, Zhao YY, Cao G. 1-Hydroxypyrene mediates renal fibrosis through aryl hydrocarbon receptor signalling pathway. Br J Pharmacol 2021; 179:103-124. [PMID: 34625952 DOI: 10.1111/bph.15705] [Citation(s) in RCA: 27] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2021] [Revised: 09/08/2021] [Accepted: 09/13/2021] [Indexed: 01/09/2023] Open
Abstract
BACKGROUND AND PURPOSE In chronic kidney disease (CKD), patients inevitably reach end-stage renal disease and require renal transplant. Evidence suggests that CKD is associated with metabolite disorders. However, the molecular pathways targeted by metabolites remain enigmatic. Here, we describe roles of 1-hydroxypyrene in mediating renal fibrosis. EXPERIMENTAL APPROACH We analysed 5406 urine and serum samples from patients with Stage 1-5 CKD using metabolomics, and 1-hydroxypyrene was identified and validated using longitudinal and drug intervention cohorts as well as 5/6 nephrectomised and adenine-induced rats. KEY RESULTS We identified correlations between the urine and serum levels of 1-hydroxypyrene and the estimated GFR in patients with CKD onset and progression. Moreover, increased 1-hydroxypyrene levels in serum and kidney tissues correlated with decreased renal function in two rat models. Up-regulated mRNA expression of aryl hydrocarbon receptor and its target genes, including CYP1A1, CYP1A2 and CYP1B1, were observed in patients and rats with progressive CKD. Further we showed up-regulated mRNA expression of aryl hydrocarbon receptor and its three target genes, plus up-regulated nuclear aryl hydrocarbon receptor protein levels in mice and HK-2 cells treated with 1-hydroxypyrene, which caused accumulation of extracellular matrix components. Treatment with aryl hydrocarbon receptor short hairpin RNA or flavonoids inhibited mRNA expression of aryl hydrocarbon receptor and its target genes in 1-hydroxypyrene-induced HK-2 cells and mice. CONCLUSION AND IMPLICATIONS Metabolite 1-hydroxypyrene was demonstrated to mediate renal fibrosis through activation of the aryl hydrocarbon receptor signalling pathway. Targeting aryl hydrocarbon receptor may be an alternative therapeutic strategy for CKD progression.
Collapse
Affiliation(s)
- Hua Miao
- Faculty of Life Science and Medicine, Northwest University, Xi'an, China
| | - Xia-Qing Wu
- Faculty of Life Science and Medicine, Northwest University, Xi'an, China
| | - Yan-Ni Wang
- Faculty of Life Science and Medicine, Northwest University, Xi'an, China
| | - Dan-Qian Chen
- Faculty of Life Science and Medicine, Northwest University, Xi'an, China
| | - Lin Chen
- Faculty of Life Science and Medicine, Northwest University, Xi'an, China
| | - Nosratola D Vaziri
- Division of Nephrology and Hypertension, School of Medicine, University of California Irvine, Irvine, California, USA
| | - Shougang Zhuang
- Department of Nephrology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.,Rhode Island Hospital and Alpert Medical School, Brown University, Providence, Rhode Island, USA
| | - Yan Guo
- Department of Internal Medicine, University of New Mexico, Albuquerque, New Mexico, USA
| | - Wei Su
- Department of Nephrology, Baoji Central Hospital, Baoji, China
| | - Shi-Xing Ma
- Department of Nephrology, Baoji Central Hospital, Baoji, China
| | - Huan-Qiao Zhang
- Department of Nephrology, Baoji Central Hospital, Baoji, China
| | - You-Quan Shang
- Department of Nephrology, Baoji Central Hospital, Baoji, China
| | - Xiao-Yong Yu
- Department of Nephrology, Shaanxi Traditional Chinese Medicine Hospital, Xi'an, China
| | - Yan-Long Zhao
- Department of Nephrology, Shaanxi Traditional Chinese Medicine Hospital, Xi'an, China
| | - Jia-Rong Mao
- Department of Nephrology, Shaanxi Traditional Chinese Medicine Hospital, Xi'an, China
| | - Ming Gao
- Department of Nephrology, Xi'an No. 4 Hospital, Xi'an, China
| | - Jin-Hua Zhang
- Department of Nephrology, Xi'an No. 4 Hospital, Xi'an, China
| | - Jin Zhao
- Department of Nephrology, Xi'an No. 4 Hospital, Xi'an, China
| | - Yuan Zhang
- Department of Nephrology, Xi'an No. 4 Hospital, Xi'an, China
| | - Li Zhang
- Department of Nephrology, Xi'an No. 4 Hospital, Xi'an, China
| | - Ying-Yong Zhao
- Faculty of Life Science and Medicine, Northwest University, Xi'an, China
| | - Gang Cao
- School of Pharmacy, Zhejiang Chinese Medical University, Hangzhou, China
| |
Collapse
|
7
|
Wang HQ, Gong XM, Lan F, Zhang YH, Xia JE, Zhang H, Guo JL, Liu M. Biopharmaceutics and Pharmacokinetics of Timosaponin A-III by a Sensitive HPLC-MS/MS Method: Low Bioavailability Resulting from Poor Permeability and Solubility. Curr Pharm Biotechnol 2021; 22:672-681. [PMID: 32634081 DOI: 10.2174/1389201021666200707134045] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2020] [Revised: 05/02/2020] [Accepted: 05/03/2020] [Indexed: 11/22/2022]
Abstract
BACKGROUND Timosaponin A-III is one of the most promising active saponins from Anemarrhena asphodeloides Bge. As an oral chemotherapeutic agent, there is an urgent need to clarify its biopharmaceutics and pharmacokinetics to improve its development potential. OBJECTIVE This research explores the bioavailability of timosaponin A-III and clarifies its absorption and metabolism mechanisms by a sensitive and specific HPLC-MS/MS method. METHODS Pharmacokinetics and bioavailability studies of timosaponin A-III were performed in Sprague- Dawley rats by oral (20 mg/kg) and intravenous administration (2 mg/kg). Control group was given the same volume of normal saline. The absorption of timosaponin A-III was investigated in a rat intestinal perfusion model in situ and a Caco-2 cell transport model in vitro. The metabolic rate of timosaponin A-III was determined in a rat liver microsome incubation system. RESULTS After the oral administration, timosaponin A-III reached Cmax of 120.90 ± 24.97 ng/mL at 8 h, and the t1/2 was 9.94 h. The absolute oral bioavailability of timosaponin A-III was 9.18%. The permeability coefficients of timosaponin A-III in four intestinal segments ranged from 4.98 to 5.42 × 10-7 cm/s, indicating a difficult absorption. A strikingly high efflux transport of timosaponin A-III was found, PappBA 3.27 ± 0.64 × 10-6 cm/s, which was abolished by a P-gp inhibitor. Rat liver microsome incubation studies showed that timosaponin A-III could hardly be metabolized, with a t1/2 of over 12 h. In addition, the solubility test showed a low solubility in PBS solution, i.e. 30.58 μg/mL. CONCLUSION Timosaponin A-III exhibited low oral bioavailability by oral and intravenous administration, which was probably caused by its low permeability and solubility. This study may provide a reference for its rational clinical use and further study on the pharmacology or toxicology of timosaponin A-III.
Collapse
Affiliation(s)
- Hai-Qiao Wang
- Department of Traditional Chinese Medicine, South Campus, Ren Ji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 201112, China
| | - Xiao-Mei Gong
- Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China
| | - Fen Lan
- Department of Pharmacy, Shanghai Changhai Hospital, Second Military Medical University, Shanghai 200433, China
| | - Yi-Han Zhang
- Department of Pharmacy, Shanghai Changhai Hospital, Second Military Medical University, Shanghai 200433, China
| | - Jin-Er Xia
- Department of Pharmacy, Shanghai Changhai Hospital, Second Military Medical University, Shanghai 200433, China
| | - Hai Zhang
- Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, Shanghai 201204, China
| | - Jia-Lin Guo
- Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, Shanghai 201204, China
| | - Min Liu
- Department of Pharmacy, Shanghai Changhai Hospital, Second Military Medical University, Shanghai 200433, China
| |
Collapse
|
8
|
Adewole KE, Attah AF, Osawe SO. Exploring phytotherapeutic approach in the management of valproic acid-induced toxicity. ADVANCES IN TRADITIONAL MEDICINE 2021. [DOI: 10.1007/s13596-021-00575-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
|
9
|
Zhang Q, Qu Z, Zhou Y, Zhou J, Yang J, Li S, Xu Q, Zhou X. In vitro study on the effect of cornin on the activity of cytochrome P450 enzymes. BMC Complement Med Ther 2021; 21:138. [PMID: 33966625 PMCID: PMC8108370 DOI: 10.1186/s12906-021-03309-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2021] [Accepted: 04/22/2021] [Indexed: 02/08/2023] Open
Abstract
Background Cornin is a commonly used herb in cardiology for its cardioprotective effect. The effect of herbs on the activity of cytochrome P450 enzymes (CYP450s) can induce adverse drug-drug interaction even treatment failure. Therefore, it is necessary to investigate the effect of cornin on the activity of CYP450s, which can provide more guidance for the clinical application of cornin. Methods Cornin (100 μM) was incubated with eight isoforms of CYP450s, including CYP1A2, 2A6, 3A4, 2C8, 2C9, 2C19, 2D6, and 2E1, in pooled human liver microsomes. The inhibition model and corresponding parameters were also investigated. Results Cornin exerted significant inhibitory effect on the activity of CYP3A4, 2C9, and 2E1 in a dose-dependent manner with the IC50 values of 9.20, 22.91, and 14.28 μM, respectively (p < 0.05). Cornin inhibited the activity of CYP3A4 non-competitively with the Ki value of 4.69 μM, while the inhibition of CYP2C9 and 2E1 by cornin was competitive with the Ki value of 11.31 and 6.54 μM, respectively. Additionally, the inhibition of CYP3A4 by cornin was found to be time-dependent with the KI/Kinact value of 6.40/0.055 min− 1·μM− 1. Conclusions The inhibitory effect of cornin on the activity of CYP3A4, 2C9, and 2E1 indicated the potential drug-drug interaction between cornin and drugs metabolized by these CYP450s, which needs further investigation and validation.
Collapse
Affiliation(s)
- Qun Zhang
- Shanghai Baoshan Aged-nursing hospital, Shanghai, 201900, China
| | - Zengqiang Qu
- Department of Invasive Technology, Shanghai Eastern Hepatobiliary Surgery Hospital, Shanghai, 200438, China
| | - Yanqing Zhou
- Department of Pharmacy, Shanghai Baoshan Luodian Hospital, No.121 Luoxi Road, Baoshan District, Shanghai, 201908, China.,Clinical research center, Shanghai Baoshan Luodian Hospital, No.121 Luoxi Road, Baoshan District, Shanghai, 201908, China
| | - Jin Zhou
- Department of Pharmacy, Shanghai Baoshan Luodian Hospital, No.121 Luoxi Road, Baoshan District, Shanghai, 201908, China.,Clinical research center, Shanghai Baoshan Luodian Hospital, No.121 Luoxi Road, Baoshan District, Shanghai, 201908, China
| | - Junwei Yang
- Department of Pharmacy, Shanghai Baoshan Luodian Hospital, No.121 Luoxi Road, Baoshan District, Shanghai, 201908, China.,Clinical research center, Shanghai Baoshan Luodian Hospital, No.121 Luoxi Road, Baoshan District, Shanghai, 201908, China
| | - Shengjian Li
- Department of Pharmacy, Shanghai Baoshan Luodian Hospital, No.121 Luoxi Road, Baoshan District, Shanghai, 201908, China.,Clinical research center, Shanghai Baoshan Luodian Hospital, No.121 Luoxi Road, Baoshan District, Shanghai, 201908, China
| | - Qiuping Xu
- Department of Pharmacy, Shanghai Baoshan Luodian Hospital, No.121 Luoxi Road, Baoshan District, Shanghai, 201908, China.
| | - Xuedong Zhou
- Clinical research center, Shanghai Baoshan Luodian Hospital, No.121 Luoxi Road, Baoshan District, Shanghai, 201908, China.
| |
Collapse
|
10
|
Liu Y, Zhang J, Wu D, Cui L. Pharmacokinetic interaction study between ligustrazine and valsartan in rats and its potential mechanism. PHARMACEUTICAL BIOLOGY 2020; 58:1290-1293. [PMID: 33355495 PMCID: PMC7759250 DOI: 10.1080/13880209.2020.1859554] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/04/2023]
Abstract
CONTEXT Ligustrazine and valsartan are commonly used drugs in the treatment of cardiac and cardiovascular disease. OBJECTIVE The interaction between ligustrazine and valsartan was studied to investigate the effect of ligustrazine on the pharmacokinetics of valsartan. MATERIALS AND METHODS The pharmacokinetics of valsartan (10 mg/kg) was investigated in Sprague-Dawley rats divided into three groups (with the pretreatment of 4 or 10 mg/kg/day ligustrazine for 10 days and without the pretreatment of ligustrazine as control) of six rats each. The in vitro experiments in rat liver microsomes were performed to explore the effect of ligustrazine on the metabolic stability of valsartan. RESULTS Ligustrazine changed the pharmacokinetic profile of valsartan. In the presence of 4 mg/kg ligustrazine, the AUC(0- t ) (385.37 ± 93.05 versus 851.64 ± 104.26 μg/L*h), t1/2 (5.46 ± 0.93 versus 6.34 ± 1.25 h), and C max (62.64 ± 9.09 versus 83.87 ± 6.15 μg/L) of valsartan was significantly decreased, and the clearance rate was increased from 10.92 ± 1.521 to 25.76 ± 6.24 L/h/kg and similar changes were observed in the group with 10 mg/kg ligustrazine (p < 0.05). The metabolic stability of valsartan was also decreased by ligustrazine as the half-life of valsartan in rat liver microsomes decreased from 37.12 ± 4.06 to 33.48 ± 3.56 min and the intrinsic clearance rate increased from 37.34 ± 3.84 to 41.40 ± 4.32 μL/min/mg protein (p < 0.05). DISCUSSION AND CONCLUSIONS Ligustrazine promoted the metabolism of valsartan via activating CYP3A4. The co-administration of ligustrazine and valsartan should be taken into account.
Collapse
Affiliation(s)
- Yang Liu
- Department of Pharmacy, The First Affiliated Hospital of Qiqihar Medical University, Fularji District, Qiqihar, China
| | - Jiaqi Zhang
- Department of Pharmacy, The First Affiliated Hospital of Qiqihar Medical University, Fularji District, Qiqihar, China
| | - Di Wu
- Central Laboratory, The First Affiliated Hospital of Qiqihar Medical University, Fularji District, Qiqihar, China
| | - Liran Cui
- Central Laboratory, The First Affiliated Hospital of Qiqihar Medical University, Fularji District, Qiqihar, China
- CONTACT Liran Cui Central Laboratory, The First Affiliated Hospital of Qiqihar Medical University, 26 Xiangyang Avenue, Fularji District, Qiqihar161041, Heilongjiang, China
| |
Collapse
|
11
|
Ji X, Ding B, Wu X, Liu F, Yang F. In vitro study on the effect of ophiopogonin D on the activity of cytochrome P450 enzymes. Xenobiotica 2020; 51:262-267. [PMID: 33115303 DOI: 10.1080/00498254.2020.1842941] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Ophiopogonin D is a commonly used herb in cardiology and pediatrics for its variuos pharmacological effects. It is necessary to investigate the effect of ophiopogonin D on the activity of cytochrome P450 enzymes (CYP450s) to provide more guidance for the clinical application of ophiopogonin D. Eight isoforms of CYP450s, including CYP1A2, 2A6, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A4 were incubated with 100 μM ophiopogonin D in pooled human liver microsomes. The inhibition model and corresponding parameters were also investigated. Ophiopogonin D exerted a significant inhibitory effect on the activity of CYP3A4, 2C9, and 2E1 in a dose-dependent manner with the IC50 values of 8.08, 12.92, and 22.72 μM, respectively (p < 0.05). The inhibition of CYP3A4 by ophiopogonin D was performed non-competitively and time-dependently with the Ki value of 4.08 μM and the KI/Kinact value of 5.02/0.050 min-1·μM-1. Whereas, ophiopogonin D acts as a competitive inhibitor of CYP2E1 and 2C9 with the Ki value of 6.69 and 11.07 μM, respectively. The inhibitory effect of ophiopogonin D on the activity of CYP3A4, 2C9, and 2E1 indicated the potential drug-drug interaction between ophiopogonin D and drugs metabolized by these CYP450s, which needs further in vivo investigation and validation.
Collapse
Affiliation(s)
- Xiaofei Ji
- Department of Pediatrics, Weifang Yidu Central Hospital, Weifang, China
| | - Baodong Ding
- Department of Pediatrics, Weifang Yidu Central Hospital, Weifang, China
| | - Xiaoyou Wu
- Department of Pediatrics, Weifang Yidu Central Hospital, Weifang, China
| | - Fengyi Liu
- Qingzhou Dongxia Central Health Center, Weifang, China
| | - Fengqi Yang
- Department of Pediatrics, Qujing First People's Hospital at Kunming Medical University, Qujing, China
| |
Collapse
|